[Pembrolizumab (melanoma, adjuvant) - Benefit assessment according to § 35a SGB V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004330
German
Original Title:
Pembrolizumab (Melanom, adjuvant)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a22-72.html
Year Published:
2022
URL for published report:
https://www.iqwig.de/download/a22-72_pembrolizumab_nutzenbewertung-35a-sgb-v_v1-1.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Melanoma
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Keywords
- Pembrolizumab
- Melanoma
- Benefit Assessment
- NCT03553836
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.